IMC Chicago’s AbCellera Biologics ABCL Stock Holding History

IMC Chicago’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$504K	Buy	144,400 +49,400	+52%	+$178K	﹤0.01%	4037
2025 Q4	$325K	Buy	95,000 +47,400	+100%	+$212K	﹤0.01%	3751
2025 Q3	$239K	Buy	+47,600	New	+$210K	﹤0.01%	3494

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IMC Chicago's ABCL Position: Q4 2025 in Review

IMC Chicago sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 92,973 shares — an estimated $415K sold.

IMC Chicago first reported a position in ABCL in Q3 2025 and held it in 1 quarter. The position peaked at $468K in Q3 2025. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

IMC Chicago reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
IMC Chicago sold 92,973 AbCellera Biologics shares in Q4 2025, an estimated $415K.
IMC Chicago first reported a position in AbCellera Biologics in Q3 2025 and held it in 1 quarter.
IMC Chicago's AbCellera Biologics position peaked at $468K in Q3 2025.
144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.